| Literature DB >> 27584874 |
Edwin Chandrasekar1, Sharon Song2, Matthew Johnson2, Aaron M Harris3, Gary I Kaufman4, David Freedman5, Michael T Quinn6, Karen E Kim6.
Abstract
INTRODUCTION: Most research on hepatitis B virus (HBV) infection in the United States is limited to Asian populations, despite an equally high prevalence among African immigrants. The purpose of this study was to determine testing and detection rates of HBV infection among African-born people residing in the Chicago metropolitan area.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27584874 PMCID: PMC5008862 DOI: 10.5888/pcd13.160162
Source DB: PubMed Journal: Prev Chronic Dis ISSN: 1545-1151 Impact factor: 2.830
Demographic Characteristics and Testing Results of African-Born Persons Recruited Through a Chain Referral Sampling Strategy, Chicago Metropolitan Area, 2012–2014
| Variable | Number (%) (N = 445) | Clinical Screening Location (%) (N = 386) | Nonclinical Screening Location (%) (N = 59) |
|
|---|---|---|---|---|
|
| ||||
| Male | 219 (49) | 186 (48) | 33 (56) | .33 |
| Female | 226 (51) | 200 (52) | 26 (44) | |
|
| ||||
| Black | 411 (93) | 353 (91) | 58 (98) | <.004 |
| White | 11 (2) | 11 (3) | 0 | |
| Other | 12 (3) | 11 (3) | 1 (2) | |
| Not indicated | 11 (2) | 11 (3) | 0 | |
|
| ||||
| <18 | 90 (20) | 90 (23) | 0 | <.001 |
| 18–39 | 190 (43) | 174 (45) | 16 (27) | |
| 40–64 | 156 (35) | 115 (30) | 41 (70) | |
| ≥65 | 9 (2) | 7 (2) | 2 (3) | |
|
| ||||
| Yes | 354 (80) | 330 (86) | 24 (41) | .005 |
| No | 83 (19) | 51 (13) | 32 (54) | |
| Unknown | 8 (2) | 5 (1) | 3 (5) | |
|
| ||||
| <10 | 310 (70) | 300 (78) | 10 (17) | <.001 |
| 10–19 | 29 (6) | 0 | 29 (49) | |
| 20–29 | 14 (3) | 0 | 14 (24) | |
| Unknown | 92 (21) | 86 (22) | 6 (10) | |
Proportion of Hepatitis B Surface Antigen and Potential Exposure Based on Hepatitis B Core Antibody Positivity Among African-Born Persons by Country of Origin, Chicago Metropolitan Area, 2012–2014
| Country of Origin | HBsAg and Anti-HBc Results | ||
|---|---|---|---|
| HBsAg Positive, No. (%) | Anti-HBc Positive | Total No. Tested | |
| Algeria | 0 | 0 | 2 |
| Benin | 0 | 0 | 1 |
| Cameroon | 0 | 0 | 4 |
| Central Africa Republic | 3 (43) | 0 | 7 |
| Chad | 0 | 0 | 6 |
| Democratic Republic of the Congo | 3 (5) | 21 (11) | 62 |
| Cote d’Ivoire (Ivory Coast) | 1 (33) | 2 (1) | 3 |
| Djibouti | 2 (50) | 0 | 4 |
| Egypt | 0 | 2 (1) | 3 |
| Eritrea | 0 | 0 | 6 |
| Ethiopia | 2 (4.5) | 2 (1) | 44 |
| Ghana | 4 (8) | 1 (.05) | 49 |
| Guinea | 0 | 0 | 1 |
| Kenya | 0 | 6 (3) | 11 |
| Liberia | 1 (33) | 0 | 3 |
| Libyan Arab Jamah | 0 | 2 (1) | 4 |
| Malawi | 0 | 0 | 2 |
| Mauritania | 0 | 1 (.05) | 2 |
| Morocco | 0 | 0 | 4 |
| Mozambique | 0 | 0 | 3 |
| Namibia | 0 | 1 (.05) | 5 |
| Niger | 0 | 0 | 2 |
| Nigeria | 4 (7) | 4 (2) | 58 |
| Rwanda | 1 (4) | 1 (.05) | 26 |
| Sierra Leone | 1 (50) | 1 (.05) | 2 |
| Somalia | 7 (15) | 13 (7) | 47 |
| Sudan | 5 (25) | 4 (2) | 20 |
| Syria | 0 | 0 | 2 |
| Tanzania | 0 | 1 (.05) | 2 |
| Togo | 0 | 1 (.05) | 8 |
| Uganda | 0 | 6 (3) | 13 |
| Zaire | 1 (3) | 0 | 34 |
| Zimbabwe | 0 | 0 | 2 |
| Other Africa | 0 | 3 (1.5) | 3 |
|
| 35 (8) | 72 (37) | 445 |
Abbreviations: anti-HBc, hepatitis B core antibody; anti-HBs, hepatitis B surface antibody; HBsAG, hepatitis B surface antigen.
194 participants had serological data for all 3 tests (HBsAg, anti-HBc, anti-HBs).
Three participants indicated “Africa” rather than a specific country.